WO2010028122A1 - Process for making bivalirudin - Google Patents

Process for making bivalirudin Download PDF

Info

Publication number
WO2010028122A1
WO2010028122A1 PCT/US2009/055853 US2009055853W WO2010028122A1 WO 2010028122 A1 WO2010028122 A1 WO 2010028122A1 US 2009055853 W US2009055853 W US 2009055853W WO 2010028122 A1 WO2010028122 A1 WO 2010028122A1
Authority
WO
WIPO (PCT)
Prior art keywords
tbu
product
segment
hcl
organic solvent
Prior art date
Application number
PCT/US2009/055853
Other languages
French (fr)
Other versions
WO2010028122A8 (en
Inventor
Tsung Yu Hsiao
Jin Guo Ding
Hung Wei Chuang
Original Assignee
Scinopharm Taiwan Ltd.
Chan, Hardy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Taiwan Ltd., Chan, Hardy filed Critical Scinopharm Taiwan Ltd.
Priority to AU2009288027A priority Critical patent/AU2009288027B2/en
Priority to CA2736126A priority patent/CA2736126C/en
Priority to EP09812204.7A priority patent/EP2349307B1/en
Priority to JP2011526190A priority patent/JP5788321B2/en
Priority to CN2009801379027A priority patent/CN102164609A/en
Publication of WO2010028122A1 publication Critical patent/WO2010028122A1/en
Priority to IL211555A priority patent/IL211555A/en
Publication of WO2010028122A8 publication Critical patent/WO2010028122A8/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • the present invention relates to the efficient commercial synthesis for the making of bivalirudin, a peptide. It is well known that bivalirudin is indicated to reduce the risk of acute ischemic complications, and is an anticoagulant and acts as a direct thrombin inhibitor. The process substantially comprises the syntheses of various fragments of the polypeptide and the coupling of the fragments to produce bivalirudin.
  • Thrombin inhibitors are synthesized by various techniques which are well known in the art. These include enzymatic cleavage of natural or recombinant hirudin, recombinant DNA techniques, solid-phase peptide synthesis, solution-phase peptide synthesis, organic chemical synthesis techniques, or a combination of these techniques . [0004] The following references disclose various techniques for producing thrombin inhibitors. (1) US 5196404 (2) US 5240913
  • the present invention provides for an efficient process of making Bivalirudin in solution that is high in yield and scalable for commercial production.
  • the process comprises the stepwise synthesis of amino acid segments Sl, S2, S3, ⁇ 4, and the coupling together of these segments to produce Bivalirudin.
  • the process of the present invention provides for the making of
  • Bivalirudin that is in high yield and of high purity compared to the solid-phase peptide synthesis method.
  • the appended claims are directed to process for making Bivalirudin and for making various novel intermediates . Recitation within these claims to first organic solvent, second organic solvent, and so forth, is meant to indicate that the organic solvents may be different or the same within the same claimed process; and that recitation of the same term for the organic solvent from one claimed process to another different claimed process does not necessarily indicate that the solvents are the same.
  • Figure 1 depicts the synthesis of the peptide Segment 1 (Sl) as disclosed in Examples 1, 2 and 3.
  • Figure 2 depicts the synthesis of the peptide Segment 2 (S2) as disclosed in Examples 4 and 5.
  • Figure 3 depicts the synthesis of the peptide Segment 3 (S3) as disclosed in Examples 6, 7 and 8.
  • Figure 4 depicts the synthesis of the peptide Segment 4 (S4) as disclosed in Examples 9 and 10.
  • Figure 5 depicts the synthesis of the
  • S2M1 (Ml of segment 2) - FmocAsn (Trt) GIyOtBu
  • S2M2 (M2 of segment 2) - Asn (Trt) GIyOtBu
  • S2M3 (M3 of segment 2) - FmocGlyAsn (Trt) GIyOtBu [00023]
  • S2M4 (M4 of segment 2 ⁇ - GlyGlyAsn (Trt) GIyOtBu [00024]
  • S2M5 (M5 of segment 2) FmocGlyGlyGlyGlyAsn (Trt) GIyOtBu [00025]
  • S2 (Segment 2) - FmocGlyGlyGlyGlyAsnGlyOH [00026]
  • S3M1 (Ml of segment 3) - BocIleProOBn [00027]
  • S3M2 (M2 of segment 3) - HCl IleProOBn [00028]
  • S3M3 (M3 of segment 3) - FmocGlu (tBu) IleProOBn [00029]
  • S3M4 (M4 of segment 3) - GIu (t
  • S3M6 (M6 of segment 3) GIu (tBu) GIu (tBu) IleProOBn
  • S3M7 (M7 of segment 3) FmocPheGlu(tBu ⁇ Glu ⁇ tBu) IleProOBn
  • EA - Ethyl acetate [00056] DIC - N, N' -Diisopropylcarbodiimide [00057] DCM - Di chloromethane [00058] DMF - N, N-Dimethyl formamide [00059] DMSO - Dimethyl sulfoxide [00060] DBU - 1, 8-Diazobicyclo [5, 4 , 0] undec-7-ene [00061] DEA - Diethanolamine [00062] DIEA - N,N-Diisoproylethylamine [00063] MTBE - Methyl tert-butyl ether [00064] NMM - N-Methylmorpholine
  • the reaction mixture was allowed to assume room, temperature for another 3 h.
  • the reaction mixture was neutralized with IN HCl ⁇ aq. ⁇ , followed by concentrated to about 3/5 volume.
  • the product in aqueous layer was precipitated out by adjusting pH to about 3 with IN HCl (aq.) .
  • the precipitated product was separated by filtration and washed with water (2 X 10 L) . Yield: 1.12 Kg
  • Example 1 The compounds from Example 1 (1.00 Kg) and Example 2 (1.32 kg) were dissolved in DMF (5 L) and HOBt (0.41 kg) was added. NMM (0.41 L) and EDCI (0.63 kg) were added and the reaction was stirred for 2 h.
  • the reaction mixture was diluted by DCM (10 L), washed with water (10 L) and concentrated to about 1/5 volume.
  • the concentrated mixture was added into methyl-t-butyl ether (MTBE, 40 L) for intermediate precipitation.
  • the precipitated intermediate was separated by filtration and washed with MTBE (2 X 20 L) to get intermediate (S1M5) .
  • the intermediate (S1M5) was dissolved in MeOH (6 L) followed by added into mixed solvents of MeOH (6 L) and IN NaOH (aq. 5.5 L) .
  • the reaction was allowed stirring for 5 h, then neutralized with HCl ⁇ aq. ⁇ , followed by concentrated.
  • the concentrated residue was extracted with DCM (15 L) after pH adjusted to about 3.
  • the organic layer was concentrated and added into MTBE (40 L) for product precipitation.
  • the precipitated product was separated by filtration and washed with MTBE (2 X 20 L) . Yield: 1.48 kg
  • the product was precipitated out by solvent replacement with n-Heptane and adding MTBE (20 L) .
  • the precipitated product was separated by filtration, washed with MTBE
  • DCM solution of intermediate (S3M4, about 7 L) DCM solution of intermediate (S3M4, about 7 L) .
  • the DCM solution of intermediate ( ⁇ 3M4) was mixed with protected amino acid FmocGlu (tBu) OH (0.86 kg) and HOBt (0.28 kg) .
  • EDCI (0.60 kg) was added and was allowed to react for 1 h to give DCM solution of intermediate (S3M5, about 7 L) .
  • DBU (0.47 L) was added into the DCM solution of intermediate (S3M5) and was allowed react for 1 h.
  • the reaction mixture was washed with water (total 9 L) and 5% Na2CO3 (aq. 3 L) to give DCM solution of intermediate (S3M6, about 7 L) .
  • Example 8 The compounds from Example 8 (1.00 Kg ⁇ and Example 5 (0.70 kg) were dissolved in DMSO (7 L) and HOBt (0.16 kg) was added. EDCI (0.48 kg ⁇ was added and the reaction mixture was allowed stirring for another 1 h, then Piperidine (1 L) was added and the reaction was allowed stirring for another 2 h. The product was precipitated out by adding water (35 L) . The precipitated product was separated by filtration and washed with water ⁇ 2 X 10 L) and MTBE (3 X 10 L) . Yield: 1.26kg
  • Example 12 The compounds from Example 12 (1.00 Kg) and Example 10 ⁇ 0.42 kg) were dissolved in DMSO (5.8 L) and HOBt (0.08 kg) was added. EDCI (0.15 kg) was added and the reaction mixture was allowed stirring continued for another 1 h.
  • the intermediate (M5) was precipitated out by adding water (24 L) and was separated by filtration and washed with water (2 X 6 L) .
  • the precipitated intermediate (M5) was dissolved in mixed solvents of water (0.08 L), TIS (0.33 L) and TFA (7.92 L) and the mixture was allowed to react for 1 h.
  • the product was precipitated out by slowly adding MTBE (29.2 L) and was separated by filtration, washed with MTBE (2 X 8.3 L) and THF (2 X 8.3 L) . Yield: 1.12 kg

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to the efficient commercial synthesis of Bivalirudin.

Description

PROCESS FOR MAKING BIVALIRUDIN
RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Patent Application Serial Number 61/190,928 which was filed on September 3, 2008. The entire content of which is herein incorporated by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
[0002] The present invention relates to the efficient commercial synthesis for the making of bivalirudin, a peptide. It is well known that bivalirudin is indicated to reduce the risk of acute ischemic complications, and is an anticoagulant and acts as a direct thrombin inhibitor. The process substantially comprises the syntheses of various fragments of the polypeptide and the coupling of the fragments to produce bivalirudin.
2 Description of the related arts
[0003] Thrombin inhibitors are synthesized by various techniques which are well known in the art. These include enzymatic cleavage of natural or recombinant hirudin, recombinant DNA techniques, solid-phase peptide synthesis, solution-phase peptide synthesis, organic chemical synthesis techniques, or a combination of these techniques . [0004] The following references disclose various techniques for producing thrombin inhibitors. (1) US 5196404 (2) US 5240913
(3) US 5425936
(4) US 5433940
(5) US 5514409
(6) US 5691311 (7) US 2007093423
(8) US 2008051558
(9) US 2008287648
(10) US 2008287650
(11) US 20090062511 (12) WO9850563
[0005] The disclosure of the above references are herein incorporated in their entirety by reference. Certain of the references disclose the solid-phase peptide synthesis for making Bivalirudin, as the synthesis can be rapidly conducted. However, this synthesis method results in low yield and high cost of manufacture.
SUMMARY OF THE INVENTION [0006] The present invention provides for an efficient process of making Bivalirudin in solution that is high in yield and scalable for commercial production. The process comprises the stepwise synthesis of amino acid segments Sl, S2, S3, Ξ4, and the coupling together of these segments to produce Bivalirudin. The process of the present invention provides for the making of
Bivalirudin that is in high yield and of high purity compared to the solid-phase peptide synthesis method. [0007] The appended claims are directed to process for making Bivalirudin and for making various novel intermediates . Recitation within these claims to first organic solvent, second organic solvent, and so forth, is meant to indicate that the organic solvents may be different or the same within the same claimed process; and that recitation of the same term for the organic solvent from one claimed process to another different claimed process does not necessarily indicate that the solvents are the same.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 depicts the synthesis of the peptide Segment 1 (Sl) as disclosed in Examples 1, 2 and 3. [0009] Figure 2 depicts the synthesis of the peptide Segment 2 (S2) as disclosed in Examples 4 and 5.
[00010] Figure 3 depicts the synthesis of the peptide Segment 3 (S3) as disclosed in Examples 6, 7 and 8. [00011] Figure 4 depicts the synthesis of the peptide Segment 4 (S4) as disclosed in Examples 9 and 10. [00012] Figure 5 depicts the synthesis of the
Bivalirudin as disclosed in Examples 11, 12 and 13.
DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED
EMBODIMENTS
[00013] The identifying reference codes of the intermediates used in the present description and schemes are defined as follows. [00014] SlMl (Ml of segment 1) - BocArg (HCl) ProOBn [00015] S1M2 (M2 of segment 1} - HCl Arg (HCl) ProOBn [00016] S1M3 (M3 of segment 1) - Boc-D-PheProOBn [00017] S1M4 (M4 of segment 1) - Boc-D-PheProOH [00018] S1M5 {M5 of segment 1} - Boc-D- PheProArg (HCl ) ProOBn [00019] Sl (Segment 1) - Boc-D-PheProArg (HCl) ProOH
[00020] S2M1 (Ml of segment 2) - FmocAsn (Trt) GIyOtBu [00021] S2M2 (M2 of segment 2) - Asn (Trt) GIyOtBu
[00022] S2M3 (M3 of segment 2) - FmocGlyAsn (Trt) GIyOtBu [00023] S2M4 (M4 of segment 2} - GlyGlyAsn (Trt) GIyOtBu [00024] S2M5 (M5 of segment 2) FmocGlyGlyGlyGlyAsn (Trt) GIyOtBu [00025] S2 (Segment 2) - FmocGlyGlyGlyGlyAsnGlyOH [00026] S3M1 (Ml of segment 3) - BocIleProOBn [00027] S3M2 (M2 of segment 3) - HCl IleProOBn [00028] S3M3 (M3 of segment 3) - FmocGlu (tBu) IleProOBn [00029] S3M4 (M4 of segment 3) - GIu (tBu) IleProOBn [00030] S3M5 (M5 of segment 3) FmocGlu (tBu) GIu (tBu) IleProOBn
[00031] S3M6 (M6 of segment 3) GIu (tBu) GIu (tBu) IleProOBn [00032] S3M7 (M7 of segment 3) FmocPheGlu(tBu}Glu{tBu) IleProOBn
[00033] S3M8 {M8 of segment 3) - H-
PheGlu (tBu) GIu (tBu) IleProOBn
[00034] S3M9 (M9 of segment 3) -
FmocAsp (tBu) PheGlu (tBu) GIu (tBu) IleProOBn [00035] S3 (Segment 3)
Asp (tBu} PheGlu (tBu) GIu (tBu) IleProOBn
[00036] S4M1 (Ml of segment 4) - FmocTyr ( tBu) LeuOtBu [00037] Ξ4M2 (M2 of segment 4) - Tyr (tBu) LeuOtBu [00038] Ξ4M3 (M3 of segment 4) FmocGlu (tBu) Tyr (tBu) LeuOtBu
[00039] Ξ4M4 (M4 of segment 4) - GIu (tBu) Tyr (tBu) LeuOtBu [00040] S4M5 (M5 of segment 4) FmocGlu (tBu) GIu (tBu) Tyr (tBu) LeuOtBu [00041] S4 (Segment 4) - GIu (tBu) GIu (tBu) Tyr (tBu) LeuOtBu [00042] Ml - Fmoc
GlyGlyGlyGlyAsnGlyAsp {tBu) PheGlu (tBu) GIu (tBu> IleProOBn
[00043] M2
GlyGlyGlyGlyAsnGlyAsp (tBu) PheGlu (tBu) GIu (tBu) IleProOBn
[00044] M3 - Boc- D- PheProArg (HCl ) ProGlyGlyGlyGlyGlyAsnGlyAsp (tBu)
PheGlu (tBu) GIu (tBu} IleProOBn
[00045] M4 - Boc-D-
PheProArg (HCl) ProGlyGlyGlyGlyGlyAsnGlyAsp (tBu)
PheGlu (tBu) GIu (tBu) IleProOH [00046] M5 - Boc- D-
PheProArg (HCl) ProGlyGlyGlyGlyGlyAsnGlyAsp (tBu)
PheGlu (tBu) GIu (tBu) IleProGlu (tBu) GIu (tBu) Tyr (tBu) LeuOtBu
[00047] The abbreviations used in the present description are defined as follows. [00048] Boc - tert-Butyloxycarbonyl
[00049] Bn - benzyl
[00050] Fmoc - 9-Fluorenylmethyloxycarbonyl
[00051] Trt - Trityl
[00052] tBu - tert-Butyl
[00053] HOBt - N-hydroxybenzotriazole
[00054] EDCl - Ethyl {3-dimethylaminopropyl) carbodiimide hydrochloride
[00055] EA - Ethyl acetate [00056] DIC - N, N' -Diisopropylcarbodiimide [00057] DCM - Di chloromethane [00058] DMF - N, N-Dimethyl formamide [00059] DMSO - Dimethyl sulfoxide [00060] DBU - 1, 8-Diazobicyclo [5, 4 , 0] undec-7-ene [00061] DEA - Diethanolamine [00062] DIEA - N,N-Diisoproylethylamine [00063] MTBE - Methyl tert-butyl ether [00064] NMM - N-Methylmorpholine
[00065] The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention.
EXAMPLE 1 Preparation of HCl Arg (HCl) ProOBn (S1M2)
[00066] The protected amino acid BocArgOH*HCl*H20 (1.00 Kg) and ProOBn. HCl (0.77 kg) were dissolved in DMF (3 L) and HOBt (0.45 kg) was added. DIC (0.57 L) and NMM (0.37
L} were added and the reaction was stirred for another
15 h. The reaction mixture was filtered and the intermediate was precipitated out by addition of Acetone (30 L) . The precipitated intermediate (SlMl) was separated by filtration and washed with Acetone (2 X 6
L) . The precipitated intermediate (SlMl) was dissolved in HCl (g)/ . IPA (13%, 5 L) and the reaction was stirred for 6 h. The product was precipitated out by added into pre-cooled methyl-t-butyl ether (MTBE, 40 L) . The precipitated product was separated by filtration and washed with MTBE (2 X 20 L) . Yield: 1.06 Kg
EXAMPLE 2 Preparation of Boc-D-PheProOH (S1M4)
[00067] The protected amino acid Boc-D-PheOH (1.00 Kg) and ProOBn. HCl (0.93 kg) were dissolved in DCM (8 L) and HOBt (0.56 kg) was added. DIEA (0.72 L) and EDCI (0.87 kg) were added and reaction was stirred for 2 h. The reaction mixture was washed with 5% sodium bicarbonate solution (10 L), 2.5% Citric acid solution (5 L} and 5% sodium bicarbonate solution (5 L) and was vaβuurat—fee- drynooo concentrated to get intermediate of yellow oil (S1M3) . The intermediate (S1M3) was cooled to 20°C and IN NaOH (aq. 7.5 L) was added. The reaction mixture was allowed to assume room, temperature for another 3 h. The reaction mixture was neutralized with IN HCl {aq.}, followed by concentrated to about 3/5 volume. The product in aqueous layer was precipitated out by adjusting pH to about 3 with IN HCl (aq.) . The precipitated product was separated by filtration and washed with water (2 X 10 L) . Yield: 1.12 Kg
EXAMPLE 3
Preparation of Boc-D-PheProArg (HCl) ProOH (Sl)
[00068] The compounds from Example 1 (1.00 Kg) and Example 2 (1.32 kg) were dissolved in DMF (5 L) and HOBt (0.41 kg) was added. NMM (0.41 L) and EDCI (0.63 kg) were added and the reaction was stirred for 2 h. The reaction mixture was diluted by DCM (10 L), washed with water (10 L) and concentrated to about 1/5 volume. The concentrated mixture was added into methyl-t-butyl ether (MTBE, 40 L) for intermediate precipitation. The precipitated intermediate was separated by filtration and washed with MTBE (2 X 20 L) to get intermediate (S1M5) . The intermediate (S1M5) was dissolved in MeOH (6 L) followed by added into mixed solvents of MeOH (6 L) and IN NaOH (aq. 5.5 L) . The reaction was allowed stirring for 5 h, then neutralized with HCl {aq.}, followed by concentrated. The concentrated residue was extracted with DCM (15 L) after pH adjusted to about 3. The organic layer was concentrated and added into MTBE (40 L) for product precipitation. The precipitated product was separated by filtration and washed with MTBE (2 X 20 L) . Yield: 1.48 kg
EXAMPLE 4
Preparation of GlyGlyAsn(Trt) GIyOtBu (S2M4)
[00069] The protected amino acid GlyOtBu'HCl (0.30 kg) and FmocAsn(Trt) OH {1 kg) and HOBt (0.24 kg) were stirred in DCM (5 L) . NMM (0.19 L) and EDCI (0.48 kg) was added to the mixture. The reaction mixture was reacted for 3 h to give the DCM solution of intermediate (S2M1) . DBU (1 L} was added to the DCM solution of intermediate (S2M1) and reacted for 3 h. The reaction mixture was washed with water (3 X 3.5 L) to give DCM solution of intermediate (S2M2, about 5L) . Protected amino acid FmocGlyGlyOH (0.59 kg} and HOBT (0.14 kg) were added to the DCM solution of intermediate (S2M2) and EDCI (0.48 kg) was added. The reaction mixture was reacted for 6 h to give solution of intermediate (S2M3) . DBU (1 L) was added to the solution of intermediate (S2M3) and reacted for 1 h. The reaction mixture was washed with water {3 X 15 L) . The organic layer was concentrated and the product was precipitated out by adding MTBE {40 L) . The precipitated product was separated by filtration and washed with MTBE (2 X 7 L) . Yield 0.71 kg EXAMPLE 5
Preparation of FmocGlyGlyGlyGlyAsnGlyOH {S2)
[00070] The compounds from Example 4 (1.00 Kg) and protected amino acid FmocGlyGlyOH (0.59 kg) were dissolved in mixed solvent of DMF/ DCM (3 L/ 10 L) and HOBt (0.14 kg) was added. EDCI (0.35 kg) was added to the mixture and reacted for 16 h. The intermediate
(S2M5) was precipitated out by adding mixed solvent of n-heptane/ MTBE (30 L/ 30 L) and separated by filtration, then washed with MTBE (2 X 5 L) . The precipitated intermediate (S2M5) was stirred in mixed solvents of water (0.39 L), TIS (0.39 L) and TFA (14.8
L) and reacted for 2 h. The reaction mixture was precipitated out by adding MTBE (80 L) and separated by filtration, washed with MTBE (2 x 8 L} . Yield: 0.72 kg
Example 6 Preparation of HCl* IleProOBn (S3M2)
[00071] The protected amino acids ProOBn*HCl (1.00 kg) and BocIleOH 0.5 H2O (1.04 Kg) were dissolved in DCM (6
L) and HOBt (0.56 kg) was added. NMM (0.84 L) and EDCI
(1.19 kg) were added and the reaction was allowed to stir for 4 h. The reaction mixture was washed with water
(total 9 L) and NaHCO3 (aq. 3 L) followed by cocentrated fee—dryness to give the intermediate (S3M1, Foam) . The intermediate (S3M1) was dissolved into HCl (g) / IPA
(about 13%, 3 L) and stirring continued for another 3 h.
The product was precipitated out by solvent replacement with n-Heptane and adding MTBE (20 L) .The precipitated product was separated by filtration, washed with MTBE
(total 16 L) . Yield: 1.4 kg Example 7
Preparation of FmocGlu (tBu) GIu (tBu) IleProOBn (S3M7)
[00072] The compounds from Example 6 (1.00 Kg), protected amino acid FmocGlu (tBu) OH (0.87 kg) and HOBt (0.28 kg) were dissolved in DCM (7 L) . NMM (0.35 L) and EDCI (0.60 kg) were added and the reaction was allowed to stir for 1 h to give DCM solution of intermediate (S3M3, about 7 L) . DBU (0.47 L) was added into the DCM solution of intermediate (S3M3) and was allowed react for 1 h. The reaction was washed with water (total 9 L) and 5% Na2CO3
(aq. 3 L) to give DCM solution of intermediate (S3M4, about 7 L) . The DCM solution of intermediate (Ξ3M4) was mixed with protected amino acid FmocGlu (tBu) OH (0.86 kg) and HOBt (0.28 kg) . EDCI (0.60 kg) was added and was allowed to react for 1 h to give DCM solution of intermediate (S3M5, about 7 L) . DBU (0.47 L) was added into the DCM solution of intermediate (S3M5) and was allowed react for 1 h. The reaction mixture was washed with water (total 9 L) and 5% Na2CO3 (aq. 3 L) to give DCM solution of intermediate (S3M6, about 7 L) . The DCM solution of intermediate (S3M6) was mixed with protected amino acid FmocPheOH (0.78 kg) and HOBt (0.28 kg} . EDCI (0.60 kg) was added and was allowed to react for 1 h. The product was precipitated out by slowly adding MTBE {20 L) and was separated by filtration and washed with MTBE (3 L) . The intermediate (S3M1) was dissolved into HCl (g) / IPA (about 13%, 3 L) and stirring continued for another 3 h. The product was precipitated out by solvent replacement with n-Heptane and adding MTBE (20 L) .The precipitated product was separated by filtration, washed with MTBE (total 16 L) . Yield: 1.84 kg Example 8
Preparation of AspPheGlu (tBu) GIu (tBu) IleProOBn (S3)
[00073] The compound from Example 7 (1.00 Kg) was dissolved in DCM (10 L) . DBU (0.22 L} was added and the reaction was allowed to react for another 1 h. The reaction mixture was washed with water (total 9 L) and 5% Na2CO3 {aq. 3 L) to give DCM solution of intermediate (S3M8, about 10 L) . The DCM solution of intermediate (S3M8) was mixed with protected amino acid ITmocAsp(tBu)OH (0.38 kg) and HOBt (0.13 kg) . EDCI (0.27 kg) was added into the mixture and was allowed to react for 1 h to give DCM solution of intermediate (S3M9, about 10 L) . DBU (0.22 L) was added into the DCM solution of intermediate (S3M9) and was allowed to react for another 1 h. The reaction mixture was washed with water (total 9 L) and 5% Na2CO3 (aq. 3 L) . The product was precipitated out by slowly adding mixed solvent of n-Heptane/ MTBE =1/ 1(35 L) . The precipitated product was separated by filtration and washed with MTBE (6 L) . Yield: 0.90 kg
Example 9 Preparation of GIu (tBu) Tyr (tBu) LeuOtBu (S4M4)
[00074] The protected amino acids FmocTyr (tBu) OH (1.00 kg) and LeuOtBuΗCl (0.50 kg) were dissolved in DCM (8 L) and HOBt (0.33 kg) was added. DIEA (0.44 L) and EDCI (0.50 kg) were added and the reaction mixture was stirred for 2 h. DEA (2.27L) was added and the reaction mixture was allowed to react for 2 h. The reaction mixture was neutralized by IN HCl (aq.) and the resulting mixture was further washed by 5% Na2CO3 (aq. about 5.3 L) to give DCM solution of intermediate {S4M2, about 8L) . The DCM solution of intermediate (S4M2) was mixed with protected amino acid FmocGlu (tBu) OH (0.93 kg) and HOBt (0.32 kg) . EDCI (0.63 kg) was added and the reaction mixture was allowed react for 2 h. DEA (2.27L) was added to the reaction and allowed to react for another 3 h followed by washed with water (2 X15 L) . The organic layer was diluted by n-Heptane (30 L) followed by concentrated to about 25 L and the product was precipitated out by adding another parts of n-Heptane ( 5 L) . The precipitated product was separated by filtration and washed with n-Heptane (10 L) . Yield: 1.09 kg
Example 10
Preparation of GIu (tBu) GIu ( tBu) Tyr ( tBu) LeuOtBu (S4)
[00075] The compounds from Example 9 (1.00 Kg), protected amino acid FmocGlu {tBu) OH (0.72 kg) and HOBt (0.25 kg) were dissolved in DCM (8 L) . EDCI (0.39 kg) was added and the reaction mixture was allowed to react for 2 h. DEA (1.77L) was added and the reaction mixture was allowed to react for 3 h followed by washed with water (2 X15 L) . The organic layer was diluted by n-Heptane (30 L) followed by concentrated to about 25 L and the product was precipitated out by adding another parts of n-Heptane ( 5 L) . The precipitated product was separated by filtration and washed with n-Heptane (10 L) . Yield: 1.11kg Example 11
Preparation of
GlyGlyGlyGlyAsnGlyAsp (tBu) PheGlu (tBu) GIu (tBu) IleProOBn
(M2)
[00076] The compounds from Example 8 (1.00 Kg} and Example 5 (0.70 kg) were dissolved in DMSO (7 L) and HOBt (0.16 kg) was added. EDCI (0.48 kg} was added and the reaction mixture was allowed stirring for another 1 h, then Piperidine (1 L) was added and the reaction was allowed stirring for another 2 h. The product was precipitated out by adding water (35 L) . The precipitated product was separated by filtration and washed with water {2 X 10 L) and MTBE (3 X 10 L) . Yield: 1.26kg
Example 12
Preparation of Boc-D-
PheProArgProGlyGlyGlyGlyAsnGlyAsp (tBu) PheGlu (tBu} GIu (tBu
) IleProOH (M4)
[00077] The compounds from Example 11 {1.00 Kg} and Example 3 (0.49 kg) were dissolved in DMSO (5.5 L) and HOBt {0.12 kg) was added. EDCI (0.16 kg) was added and the reaction mixture was allowed stirring for another 1 h. The intermediate (M3) was precipitated out by adding water (28 L) and separated by filtration and washed with water (2 X 12 L) . The precipitated intermediate (M3) was stirred in 66% ACN (aq, about 20 L) . Pd/C (10%, 0.13 Kg) was added into the mixture, followed by Hydrogen gas was introduced and reaction was allowed to agitate vigorously for 16 h. The reaction mixture was filtered and the product in the filtrate was precipitated out by azeotrope water with ACN to dryness. Yield: 1.04 Kg
Example 13 Preparation of: D- PheProArgProGlyGlyGlyGlyAsnGlyAspPheGluGluIleProGluGluTy rLeuOH »nTFAft (Crude Bivalirudin)
[00078] The compounds from Example 12 (1.00 Kg) and Example 10 {0.42 kg) were dissolved in DMSO (5.8 L) and HOBt (0.08 kg) was added. EDCI (0.15 kg) was added and the reaction mixture was allowed stirring continued for another 1 h. The intermediate (M5) was precipitated out by adding water (24 L) and was separated by filtration and washed with water (2 X 6 L) . The precipitated intermediate (M5) was dissolved in mixed solvents of water (0.08 L), TIS (0.33 L) and TFA (7.92 L) and the mixture was allowed to react for 1 h. The product was precipitated out by slowly adding MTBE (29.2 L) and was separated by filtration, washed with MTBE (2 X 8.3 L) and THF (2 X 8.3 L) . Yield: 1.12 kg
[00079] While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention. For example, reaction conditions other than the particular conditions as set forth herein above may be applicable as a consequence of variations in the reagents or methodology to prepare the compounds from the processes of the invention indicated above. It is intended, therefore, that the invention be defined by the scope of the claims which follow and that siαch claims be interpreted as broadly as is reasonable.

Claims

CLAIMSWhat is claimed:
1. A process for the preparation of Bivalirudin comprising the steps of: a) condensing the segment AspPheGlu(tBu)Glu(tBu) IleProOBn (S3) and the segment FmocGlyGlyGlyGlyAsnGlyOH (S2) in a first organic solvent; b) deprotecting the product of step a) ; c) condensing the product of step b) and the segment Boc-D-PheProArg (HCl) ProOH (51) in a second organic solvent; d) deprotecting the benzyl group of the product of step c) ; θ) condensing the product of step d) and the segment Glu(tBu)Glu(tBu)Tyr(tBu)LeuOtBu (S4) in a third organic solvent; f) deprotecting the product of step e) to obtain Bivalirudin;
2. The process according to claim 1, wherein the first, second and third organic solvents are independently selected from DCM, DMF, and DMSO.
3. The process according to claim 1, wherein the deprotection of the product of step b) is performed by using a nucleophilic base.
4. The process according to claim 1, wherein the deprotection of the product of step d) is by hydrogenation in presence of a catalyst.
5. The process according to claim 1, wherein the deprotection of the product of step f) is by reacting with a mixture of TFA/TIS/H2O to obtain Bivalirudin.
6. A compound of Segment 1, Boc-D-PheProArg (HCl) ProOH.
7. A process, wherein the preparation of Segment 1 Boc-D-PheProArg (HCl) ProOH (Sl) of claim 6 comprises the steps of: a) condensing HCl Arg (HCl) ProOBn (S1M2) and Boc-D- PheProOH (S1M4) in a first organic solvent; b) deprotecting the benzyl group of the product of step a) under alkaline condition; c) precipitating the segment Boc-D- PheProArg (HCl) ProOH (Sl) in a second organic solvent .
8. The process according to claim 7, wherein HCl Arg (HCl) ProOBn (S1M2) is prepared by: a) condensing HCl ProOBn and BocArgOH HCl in a third organic solvent; b) deprotecting the product of step a) in an acidic solution to obtain HCl Arg (HCl) ProOBn (S1M2) .
9. The process according to claim 7, wherein Boc-D- PheProOH (S1M4) is prepared by: a) condensing HCl ProOBn and Boc-D-PheOH in a fourth organic solvent; b) deprotecting the product of step a) in an alkaline solution to obtain Boc-D-PheProOH (S1M4) ,
10. A compound of Segment 2, FmocGlyGlyGlyGlyAsnGlyOH.
11. A process, wherein the preparation of Segment 2 FmocGlyGlyGlyGlyAsnGlyOH (S2) of claim 10 comprises the steps of: a) condensing HCl GIyOtBu and Fmoc Asn(Trt) in a first organic solvent; b) deprotecting the product of step a} in presence of a base; c) condensing the product of step b) and FmocGlyGlyOH in a second organic solvent; d) deprotecting the product of step c} in presence of a base;
Θ) condensing the product of step d) and
FmocGluGluOH in a third organic solvent; f) deprotecting the product of step e) to obtain the segment FmocGlyGlyGlyGlyAsnGlyOH (S2) .
12. A compound of Segment 3,
Asp(tBu) PheGlu(tBu}Glu(tBu) IleProOBn.
13. A process, wherein the preparation of Segment 3 AspPheGlu(tBu)Glu(tBu) IleProOBn (S3) of claim 12 comprising the steps of : a) condensing HCl ProOBn with BocIleOH in a first organic solvent; b) deprotecting the product of step a) under acidic condition; c) condensing the product of step b) and FmocGlu (tBu) OH in a second organic solvent to obtain a solution of intermediate; d) deprotecting the intermediate of step c) in presence of a base;
8) condensing the product of d) and FmocGlu (tBu) OH in a third organic solvent; f) deprotecting the product of e) in presence of a base; g) condensing the product of f) and FmocPheOH in a fourth organic solvent; h) deprotecting the product of step g} in presence of a base; i) condensing the product of h) and FmocAsp (tBu) OH in a fifth organic solvent; j) deprotecting the product of step i) to obtain the segment AspPheGlu {tBu) GIu (tBu} IleProOBn (S3) .
14. A compound of Segment 4,
GIu {tBu) GIu (tBu) Tyr (tBu) LeuOtBu.
15. A process, wherein the preparation of Segment 4 GIu (tBu) GIu {tBu) Tyr (tBu) LeuOtBu (S4) of claim 14 comprises the steps of : a) condensing FmocTyr (tBu) OH with HCl LeuOtBu in a first organic solvent; b) deprotecting the product of step a) in presence of a base; c) condensing the product of step b) and FmocGlu ( tBu) OH in a second organic solvent; d) deprotecting the product of step c) in presence of a base; θ) condensing the product of step d) and
FmocGlu (tBu) OH in a third organic solvent; f) deprotecting the product of step e) to obtain the segment GIu (tBu) GIu (tBu) Tyr (tBu) LeuOtBu (S4) .
PCT/US2009/055853 2008-09-03 2009-09-03 Process for making bivalirudin WO2010028122A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2009288027A AU2009288027B2 (en) 2008-09-03 2009-09-03 Process for making Bivalirudin
CA2736126A CA2736126C (en) 2008-09-03 2009-09-03 Process for making bivalirudin
EP09812204.7A EP2349307B1 (en) 2008-09-03 2009-09-03 Process for making bivalirudin
JP2011526190A JP5788321B2 (en) 2008-09-03 2009-09-03 Bivalirudine production method
CN2009801379027A CN102164609A (en) 2008-09-03 2009-09-03 Process for making bivalirudin
IL211555A IL211555A (en) 2008-09-03 2011-03-03 Process for making bivalirudin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19092808P 2008-09-03 2008-09-03
US61/190,928 2008-09-03

Publications (2)

Publication Number Publication Date
WO2010028122A1 true WO2010028122A1 (en) 2010-03-11
WO2010028122A8 WO2010028122A8 (en) 2014-11-13

Family

ID=41726391

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2009/055867 WO2010028131A1 (en) 2008-09-03 2009-09-03 Process for the preparation of pramlintide
PCT/US2009/055853 WO2010028122A1 (en) 2008-09-03 2009-09-03 Process for making bivalirudin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2009/055867 WO2010028131A1 (en) 2008-09-03 2009-09-03 Process for the preparation of pramlintide

Country Status (11)

Country Link
US (2) US8252896B2 (en)
EP (2) EP2349307B1 (en)
JP (2) JP2012502045A (en)
KR (2) KR20110056536A (en)
CN (2) CN102164609A (en)
AR (2) AR073360A1 (en)
AU (2) AU2009288036A1 (en)
CA (2) CA2736126C (en)
IL (2) IL211556A0 (en)
TW (2) TW201024316A (en)
WO (2) WO2010028131A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075983A1 (en) * 2008-12-29 2010-07-08 Lonza Braine Sa Process for the production of bivalirudin
WO2013042129A1 (en) * 2011-09-23 2013-03-28 Natco Pharma Limited Improved process for preparation of bivalirudin
USRE46830E1 (en) 2004-10-19 2018-05-08 Polypeptide Laboratories Holding (Ppl) Ab Method for solid phase peptide synthesis
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008271608A1 (en) * 2007-06-29 2009-01-08 Lonza Ag Process for the production of pramlintide
CN102180943A (en) * 2010-12-16 2011-09-14 深圳市健元医药科技有限公司 Production process of polypeptide medicament for assisting to reduce blood sugar
WO2014032257A1 (en) * 2012-08-30 2014-03-06 深圳翰宇药业股份有限公司 Method for preparing bivalirudin
CN104861045A (en) * 2014-02-20 2015-08-26 复旦大学 Cyclopeptide compound GG6F and preparation method thereof
ES2939036T3 (en) * 2019-01-24 2023-04-18 Dsm Ip Assets Bv Peptide precipitation method
CN111499719B (en) * 2020-03-19 2022-04-08 杭州固拓生物科技有限公司 Method for synthesizing pramlintide

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196404A (en) 1989-08-18 1993-03-23 Biogen, Inc. Inhibitors of thrombin
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
WO1998050563A1 (en) 1997-05-01 1998-11-12 Ppl Therapeutics (Scotland) Ltd. Methods of production of an amidated peptide through the use of a fusion protein
US20070093423A1 (en) 2005-09-14 2007-04-26 Avi Tovi Process for production of Bivalirudin
US20070213505A1 (en) * 2006-03-08 2007-09-13 David Epstein Solution Synthesis of Peptide Cell Growth Stimulators
US20080051558A1 (en) 2006-03-10 2008-02-28 Yiming Zhou Method of preparing bivalirudin
US20080287648A1 (en) 2004-10-19 2008-11-20 Lonza Ag Method for Solid Phase Peptide Synthesis
US20080287650A1 (en) 2007-03-01 2008-11-20 Avi Tovi High purity peptides
US20090062511A1 (en) 2007-09-05 2009-03-05 Raghavendracharyulu Venkata Palle Process for the preparation of bivalirudin and its pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (en) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
US6821954B2 (en) * 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
WO1999048513A1 (en) * 1998-03-23 1999-09-30 Trimeris, Inc. Methods and compositions for peptide synthesis
TW200637872A (en) * 2004-10-26 2006-11-01 Lonza Ag Thiol group protection and cyclization in solid-phase peptide synthesis
AU2008271608A1 (en) * 2007-06-29 2009-01-08 Lonza Ag Process for the production of pramlintide
CA2744627C (en) * 2008-12-29 2016-08-16 Lonza Braine Sa Process for the production of bivalirudin

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691311A (en) 1989-08-18 1997-11-25 Biogen, Inc. Methods for coating invasive devices with inhibitors of thrombin
US5196404A (en) 1989-08-18 1993-03-23 Biogen, Inc. Inhibitors of thrombin
US5425936A (en) 1989-08-18 1995-06-20 Biogen, Inc. Inhibitors of thrombin
US5433940A (en) 1989-08-18 1995-07-18 Biogen, Inc. Inhibitors of thrombin
US5514409A (en) 1989-08-18 1996-05-07 Biogen, Inc. Methods for coating invasive devices with inhibitors of thrombin
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
WO1998050563A1 (en) 1997-05-01 1998-11-12 Ppl Therapeutics (Scotland) Ltd. Methods of production of an amidated peptide through the use of a fusion protein
US20080287648A1 (en) 2004-10-19 2008-11-20 Lonza Ag Method for Solid Phase Peptide Synthesis
US20070093423A1 (en) 2005-09-14 2007-04-26 Avi Tovi Process for production of Bivalirudin
US20070213505A1 (en) * 2006-03-08 2007-09-13 David Epstein Solution Synthesis of Peptide Cell Growth Stimulators
US20080051558A1 (en) 2006-03-10 2008-02-28 Yiming Zhou Method of preparing bivalirudin
US20080287650A1 (en) 2007-03-01 2008-11-20 Avi Tovi High purity peptides
US20090062511A1 (en) 2007-09-05 2009-03-05 Raghavendracharyulu Venkata Palle Process for the preparation of bivalirudin and its pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2349307A1

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46830E1 (en) 2004-10-19 2018-05-08 Polypeptide Laboratories Holding (Ppl) Ab Method for solid phase peptide synthesis
WO2010075983A1 (en) * 2008-12-29 2010-07-08 Lonza Braine Sa Process for the production of bivalirudin
JP2012514015A (en) * 2008-12-29 2012-06-21 ロンザ・ブレーヌ・エスエー Bivalirudine production method
US8921517B2 (en) 2008-12-29 2014-12-30 Lonza Braine Sa Process for the production of bivalirudin
WO2013042129A1 (en) * 2011-09-23 2013-03-28 Natco Pharma Limited Improved process for preparation of bivalirudin
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products

Also Published As

Publication number Publication date
EP2349307B1 (en) 2015-03-04
JP5788321B2 (en) 2015-09-30
WO2010028122A8 (en) 2014-11-13
US20100056755A1 (en) 2010-03-04
EP2334314A4 (en) 2012-03-21
KR20110056536A (en) 2011-05-30
AU2009288027B2 (en) 2014-01-16
CN102164608A (en) 2011-08-24
TW201024316A (en) 2010-07-01
AU2009288027A1 (en) 2010-03-11
CA2736126C (en) 2016-11-29
JP2012502044A (en) 2012-01-26
AR073360A1 (en) 2010-11-03
AR073544A1 (en) 2010-11-17
TW201014867A (en) 2010-04-16
CA2736126A1 (en) 2010-03-11
US20100081788A1 (en) 2010-04-01
EP2349307A1 (en) 2011-08-03
TWI395752B (en) 2013-05-11
IL211555A (en) 2014-07-31
WO2010028131A1 (en) 2010-03-11
AU2009288036A2 (en) 2011-09-08
IL211555A0 (en) 2011-05-31
EP2349307A4 (en) 2012-03-21
US8252896B2 (en) 2012-08-28
JP2012502045A (en) 2012-01-26
AU2009288036A1 (en) 2010-03-11
CA2736113A1 (en) 2010-03-11
EP2334314A1 (en) 2011-06-22
KR101634830B1 (en) 2016-06-29
AU2009288027A2 (en) 2011-11-03
KR20110069048A (en) 2011-06-22
IL211556A0 (en) 2011-05-31
CN102164609A (en) 2011-08-24

Similar Documents

Publication Publication Date Title
AU2009288027B2 (en) Process for making Bivalirudin
US9169187B2 (en) Method of making peptides using diphenylmethane compound
JP5996618B2 (en) Bivalirudine production method
US20100249370A1 (en) Process for the production of pramlintide
WO2012165545A1 (en) Method for producing peptide
US20110288235A1 (en) Process for the Preparation of Pramlintide
KR20210046730A (en) Solution phase route to WNT hexapeptide
JP5119159B2 (en) Method for producing peptide thioester
WO2021026800A1 (en) Method for synthesizing degarelix acetate
WO2007130275A2 (en) Composition and method for the release of protected peptides from a resin
EP1584625A1 (en) Method of preparing tripeptide intermediates for the preparation of LHRH antagonists
NO317728B1 (en) New peptide active substance and preparation thereof
WO2022149612A1 (en) Method for producing peptide
CN110330552A (en) The synthetic method of acetic acid Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2
CN111499719A (en) Method for synthesizing pramlintide
Babu et al. N-Fmoc-Peptide azides: Synthesis, isolation, characterization and utility in the extension of peptide chains

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980137902.7

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09812204

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009288027

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2011526190

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2736126

Country of ref document: CA

Ref document number: 1481/CHENP/2011

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009812204

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009288027

Country of ref document: AU

Date of ref document: 20090903

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117007669

Country of ref document: KR

Kind code of ref document: A